↓ Skip to main content

ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI)

Overview of attention for article published in Perspectives in Drug Discovery and Design, February 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (90th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

blogs
1 blog
wikipedia
14 Wikipedia pages

Citations

dimensions_citation
142 Dimensions

Readers on

mendeley
114 Mendeley
citeulike
5 CiteULike
Title
ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI)
Published in
Perspectives in Drug Discovery and Design, February 2009
DOI 10.1007/s10822-009-9260-9
Pubmed ID
Authors

Wendy A. Warr

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 114 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 4%
Brazil 3 3%
United Kingdom 3 3%
Netherlands 2 2%
Germany 2 2%
Sweden 2 2%
India 2 2%
Portugal 1 <1%
Austria 1 <1%
Other 4 4%
Unknown 90 79%

Demographic breakdown

Readers by professional status Count As %
Researcher 28 25%
Student > Bachelor 25 22%
Student > Ph. D. Student 16 14%
Student > Master 9 8%
Other 8 7%
Other 12 11%
Unknown 16 14%
Readers by discipline Count As %
Chemistry 22 19%
Agricultural and Biological Sciences 22 19%
Pharmacology, Toxicology and Pharmaceutical Science 20 18%
Computer Science 15 13%
Biochemistry, Genetics and Molecular Biology 8 7%
Other 8 7%
Unknown 19 17%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 November 2023.
All research outputs
#3,780,850
of 25,457,858 outputs
Outputs from Perspectives in Drug Discovery and Design
#131
of 949 outputs
Outputs of similar age
#18,348
of 186,224 outputs
Outputs of similar age from Perspectives in Drug Discovery and Design
#2
of 5 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 949 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 186,224 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.